Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4572198 | 0.80 | PDE8B (0.34) | — | |
| SCHEMBL4572201 | 0.75 | RET (0.48) | ADORA2AADORA1PIK3CGDYRK1APIK3CD | |
| SCHEMBL4572207 | 0.73 | PIK3CD (0.36) | ADORA2AADORA1PIK3CGPIK3CD | |
| SCHEMBL4572205 | 0.73 | PIK3CD (0.36) | ADORA2AADORA1PIK3CGPIK3CD | |
| SCHEMBL21293809 | 0.67 | ADORA2A (0.48) | ADORA2AADORA1PIK3CGDYRK1APIK3CD | |
| SCHEMBL22494304 | 0.66 | MTOR (0.49) | — | |
| SCHEMBL30382413 | 0.66 | MTOR (0.49) | — | |
| SCHEMBL25678087 | 0.66 | RET (0.52) | ADORA2APIK3CGDYRK1APIK3CD | |
| SCHEMBL22494285 | 0.66 | MTOR (0.48) | ADORA2AADORA1CYP3A4 | |
| SCHEMBL30382542 | 0.66 | MTOR (0.48) | ADORA2AADORA1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PDE5A 690/4885ADORA2A 1165/4885ADORA1 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.